1
. Various terms have been used to describe these disorders (Box 1), but because these terms were confusing and/or misleading, an international consensus by the non-profit organization Kidney Disease Improving Global Outcomes (KDIGO) was reached to use the term ADTKD to describe these diseases, with a subclassification based on the underlying genetic defect. The introduction of this unifying terminology, which has now been globally adopted, has led to the identification of an increasing number of cases. Indeed, data suggest that ADTKD is one of the more common monogenic kidney diseases after autosomal dominant polycystic kidney disease (ADPKD) 2 and type IV collagen mutations 3 .
Several genes with disease-causing mutations have been identified in ADTKD. The most studied amongst them are: UMOD, encoding uromodulin, which is the most abundant protein secreted in normal urine and has multiple roles in kidney physiology, including salt handling, protection against infections and kidney stones and immunomodulation [4] [5] [6] [7] [8] ; MUC1, which encodes transmembrane epithelial mucin 1 and has roles in epithelial barrier protection 9 ; REN, encoding preprorenin, which is converted to prorenin and the endopeptidase renin, and has a role in regulating blood pressure and electrolyte balance 10 ; and HNF1B, encoding homeodomain-containing transcription factor hepatocyte nuclear factor 1β (HNF1β), which has a role in the development of several organs, including the kidneys 11 . When an affected gene is identified, it should be added as a suffix to the term ADTKD, allowing further subclassification of the disease (TaBle 1) . It should be noted that mutations in UMOD, MUC1, HNF1B and REN are only detected in ~50-60% of the ADTKD probands, indicating the involvement of other genes that are yet to be identified. In these unsolved cases, mutations in several other genes, including SEC61A1 (ref.
12
), should be considered. The differential diagnosis of ADTKD should include atypical ADPKD-ADTKD due to mutations in DNAJB11 (ref. 13 ), nephronophthisis (due to mutations in NPHP1) 14, 15 , PAX2-related disorders 16 and mutations in mitochondrial DNA 17 
(Box 2).
A central characteristic of ADTKD, which contri buted to the lack of recognition of the disease entity, is the non-specific nature of the clinical, biological and pathological features 1 . Affected individuals, for example, present with progressive CKD, absent-to-mild proteinuria, normal or slightly elevated blood pressure, and kidneys of normal (or small) size. A family history compatible with dominant inheritance is often present but frequently unnoticed by the clinician. Renal histo logy shows Autosomal dominant tubulointerstitial kidney disease interstitial fibrosis and tubular atrophy, with normal glomeruli. These features are of paradigmatic relevance, considering that tubulointerstitial fibrosis represents a common pathological feature of CKD that is highly correlated with CKD progression irrespective of its aetiology 18 . Next to peritubular fibroblasts, peri cytes and nonresident fibrocytes, tubular cells can contribute to abnormal matrix accumulation through profibrotic signals the nature of which nature remains largely elusive 19 .
The clinical manifestations of diseases caused by mutations in UMOD, MUC1 and REN primarily affect the kidney. By contrast, the pleiotropic functions of HNF1β as a transcription factor in several tissues (including the kidney, pancreas, liver and urogenital tract) results in variable extra-renal manifestations, with a minority of patients presenting with tubulointerstitial fibrosis and slowly progressive CKD 20, 21 . Mutations in SEC61A1, coding for the α1 subunit of the SEC61 translocon pore, cause a syndromic form of progressive CKD with small, dysplastic kidneys, which may present with simple cysts, congenital anaemia, intrauterine or postnatal growth retardation, and neutropenia causing recurrent cutaneous abscesses 12 
.
This Primer highlights the different subtypes of ADTKD, including discussions of the distinct genetic and clinical features, as well as the distinct mechanisms of disease.
Epidemiology
The epidemiology of ADTKD cannot be accurately determined due to the rarity of these conditions, their recent clinical characterization and a presumably high rate of underdiagnosis. There is no evidence so far that the prevalence of the disease varies significantly between national, geographic and ethnic populations, and no sex difference in ADTKD prevalence or clinical manifestations has been reported. However, there is likely a decreased recognition of this condition in African-American individuals due to decreased access to care 22 and a high underlying prevalence of CKD due to APOL1-related disease 23 , which may lead to a less intensive search for a diagnosis.
Prior to the year 2000, only a handful of cases of ADTKD were reported worldwide. In 2019, in a study of 3,315 patients with CKD in the USA, 307 had a monogenic disorder, including 9 individuals with UMOD mutations, accounting for 3% of the monogenic dis orders associated with CKD and 0.3% of all individuals with CKD in the cohort 3 . Similar numbers were observed in a cohort of adult Irish patients with CKD, with mutations in UMOD in 3 out of 114 families (~2.6%) 24 . A census of ADTKD in Austria, based on a randomly selected sample, yielded a prevalence of 1.67 cases per million 25 , which is most likely an underestimation as a single centre, retrospective study in kidney transplant recipients showed ADTKD-UMOD in 5 out of 911 transplanted patients 26 . In Ireland, 14 patients from 3 families with ADTKD-UMOD were identified, resulting in a prevalence of ~3 cases per million 27 . A recent survey of a single tertiary centre in England estimated the prevalence of ADTKD at 16 per million and ADTKD-UMOD at 9 per million 2 . One percent of patients with CKD stages 3-5 and 2% of patients with ESRD had ADTKD-UMOD, making it the most common monogenic kidney disease after collagen IV mutations and ADPKD 2 . These results suggest that ADTKD-UMOD is more frequent than expected and that the underdiagnosis is partly due to the lack of distinctive clinical features.
Given that testing for ADTKD-MUC1 is particularly challenging (see the section Diagnosis, screening and prevention), its availability as a clinical test is limited. The Broad Institute in the USA provides free clinical testing for MUC1 mutations and is the only centre in the country that provides MUC1 genotyping approved under the Clinical Laboratory Improvement Amendments. There are 206 living people in the USA who have been identified as having ADTKD-MUC1, suggesting a prevalence of 0.7 per million individuals. In the Irish study, 19 patients from 3 families were identified with ADTKD-MUC1, which can be extrapolated to a prevalence of ~4 cases per million 27 . Dominant mutations and gene deletions in HNF1B are an important monogenic cause of developmental kidney disease in children. The exact prevalence of HNF1B gene anomalies in the general population is thus far unknown, but many cases are likely to be undetected owing to the variable phenotype and frequency of de novo gene deletions. In patients with renal anomalies, the HNF1B
. The term familial juvenile hyperuricaemic nephropathy (FJHN) has also been used to describe ADTKD -and indeed gout and hyperuricaemia caused by a lower fractional excretion of urate are frequently described in patients harbouring UMOD, REN and HNF1B mutations 10, 21, 66, 80 . However, hyperuricaemia and gout are not patho gnomonic for ADTKD. Terms such as hereditary interstitial kidney diseases and tubulointerstitial nephritis were also used before the adoption of the ADTKD terminology 1, 150, 151 . The use of such variable and/or misleading nomenclature and the lack of uniform diagnostic criteria have hampered both the detection and study of these diseases. mutation detection rate is in the range of 5-31%, depending on the study cohort 28 . In contrast to HNF1A gene anomalies, mutations in HNF1B are a rare cause of monogenic diabetes, being identified in <1% of cases of maturityonset diabetes of the young 29 . In one study, a patient with a mutation in HNF1B was identified among 307 individuals with monogenic disorders from 3,315 US patients with CKD 3 . In the Irish adult CKD study, mutations in HNF1B were identified in one family with tubulointerstitial kidney disease and in one family with isolated congenital anomalies of the kidney and the urinary tract -that is, two mutations in a total of 114 families 24 . ADTKD-REN is rarer and has so far only been identified in ~20 families worldwide 10, [30] [31] [32] . Mutations in SEC61A1 are even rarer, being reported in two families with congenital anaemia, neutropenia (in one family) and tubulointerstitial kidney disease 12 . Two other affected families with SEC61A1 mutations have been described to have a defect in plasma cell development, recurrent infections and an unknown renal phenotype 33 . The age of onset of the different subtypes varies. For ADTKD-UMOD, affected individuals may present in their teenage years with gout. CKD is often first diagnosed in the late teen years or early twenties. For those with ADTKD-MUC1, CKD is the primary mode of presentation, which again usually starts in the early twenties. Patients with ADTKD-REN may present as early as infancy with anaemia, hyperkalaemia and CKD. ADTKD-HNF1B may present in childhood with genitourinary abnormalities, in the teenage years with gout or diabetes, and in the third decade of life with CKD. The age of onset of ESRD requiring renal replacement therapy varies widely among and within families, and usually lies between the ages of 20 years and 80 years, with most individuals requiring renal replacement therapy between the ages of 30 years and 50 years 1 . In ADTKD-HNF1B, renal dysplasia may lead to ESRD in childhood 20 .
Mechanisms/pathophysiology
Although UMOD is expressed exclusively in the nephron, the other known genes involved in ADTKD encode proteins whose expression is not confined to the kidney tubule (TaBle 1) . Recent studies have provided critical insights into distinct disease mechanisms that lead to CKD.
ADTKD-UMOD
Among ADTKD forms, ADTKD-UMOD is the condition that has had the most extensive mechanistic investigations. UMOD encodes uromodulin (previously known as Tamm-Horsfall glycoprotein), the most abundant protein in normal human urine 34 . Uromodulin is also found in the blood at concentrations that are ~1,000 times lower than in urine [35] [36] [37] . Uromodulin is a kidney-specific protein that is exclusively produced by the epithelial cells lining the thick ascending limb (TAL) of the loop of Henle and the initial part of the distal convoluted tubule (DCT) 38 . These tubular segments of the nephron are primarily responsible for the active reabsorption of sodium, potassium and chloride ions ( fig. 1 ).
Function. Both urinary and circulating levels of uromodulin are associated with renal function and mass 36, [39] [40] [41] . Studies in Umod-knockout mice and cellular systems have demonstrated that uromodulin has multiple roles -it protects against urinary tract infections by binding The term ADTKD-NOS (not otherwise specified) refers to all ADTKD cases not tested or for which genetic testing did not provide conclusive results. This category also includes additional ADTKD subtypes for which the causal mutated gene is yet to be identified. For example, mutations in DNAJB11 have been associated with some features of ADTKD, such as non-enlarged cystic kidneys and progressive interstitial fibrosis, suggesting that they could underlie a new ADTKD subtype 13 . directly to type 1-fimbriated uropathogenic Escherichia coli, which prevents the adhesion of bacteria to urothelial cells 42, 43 , and it decreases the risk of kidney stone formation by directly binding calcium oxalate crystals 44 . Studies primarily based in mouse models and population genetics suggest that uromodulin also has roles in blood pressure control and an ability to concentrate the urine. Indeed, the expression of uromodulin positively correlated with the activity of the sodium cotransporters NKCC2 (solute carrier family 12 member 1) and NCC (solute carrier family 12 member 3) in the TAL and DCT segments, respectively, which have crucial roles in terms of blood pressure control and urinary concentrating ability 38, 45 . Additionally, uromodulin exerts an immunomodulatory function that plays a protective part during acute kidney injury, wherein uromodulin inhibits chemokine signalling (which reduces damage to neighbouring proximal tubule cells) and stimulates macrophage phagocytic activity and the macrophage transition from proinflammatory (M1) to prohealing (M2) in the recovery phase 46, 47 .
Pathogenesis.
To date, 135 mutations in UMOD have been reported; with the exception of 6 in-frame deletions (4%), all the mutations are missense changes. Of these reported mutations, 63% involve missense changes that directly alter connectivity of disulfide bonds (of which there are 24 in the protein) by replacing 1 of the 48 conserved cysteine residues or by introducing a cysteine residue. The remaining 37% of missense changes affect residues other than cysteine. Studies on different uromodulin mutants expressed in a variety of cell systems have conclusively established that the primary effect of UMOD mutations is the endoplasmic reticulum (ER) retention of the mutant protein, probably due to protein misfolding 6, 48, 49 , ascribing ADTKD-UMOD as an ER storage disease. Intracellular accumulation of mutant uromodulin induces ER stress and the unfolded protein response (UPR) 50 as an adaptive response to increasing amounts of misfolded protein within the ER 51 ( fig. 2) .
Analysis of uromodulin localization in kidney biopsy specimens from patients with ADTKD-UMOD shows loss of the typical protein signal on the apical plasma membrane of TAL epithelial cells and its accumulation in large intracellular aggregates that colocalize with ER markers 5, 6, 48 . Consistently, the few available electron microscopy analyses show the presence of fibrillar material in expanded ER stacks, likely consisting of aggregated mutant uromodulin and indicating ER storage disease 48, 52 . Intracellular accumulation of mutant uromodulin is reflected by a dramatic reduction of its concentration in the urine and blood of patients with ADTKD-UMOD 5, 48, 53, 54 . Furthermore, cells transfected with mutant uromodulin showed increased rates of apoptosis that were rescued by treatment with colchicine, probenecid, topiroxostat and the chemical chaperone sodium 4-phenylbutyrate (4-PBA). The underlying mechanisms are not clear, with the exception of 4-PBA, which partially restored trafficking of mutant uromodulin along the secretory pathway [55] [56] [57] . However, 4-PBA, which is used to treat disorders of the urea cycle, did not rescue the mutant uromodulin trafficking defect nor the phenotype in vivo 58 , suggesting that the use of 4-BPA is not warranted in ADTKD-UMOD.
Six mouse models of ADTKD-UMOD expressing diverse mutations have been generated using transgenesis 59, 60 , N-ethyl-N-nitrosourea-mutagenesis 61, 62 and mutation knock-in through homologous recombination 63, 64 . All mouse models show ER retention and aggregation of mutant uromodulin, leading to ER expansion and marked reduction of urinary uromodulin levels ( fig. 2 ). The accumulation of mutant uromodulin damages the TAL segment, with either necrosis or apoptosis of epithelial cells, causing defects in urine concentration and progressive loss of kidney function. These mouse findings recapitulate observations made in kidney biopsy specimens from patients, that is, tubulointerstitial lesions with infiltration of inflammatory cells, fibrosis, tubular atrophy and cystic dilation. Intracellular accumulation of mutant uromodulin in ADTKD-UMOD mice induces ER stress, UPR [62] [63] [64] and secondary dysfunction of mitochondria 62 or defective protein homeostasis and autophagy in TAL cells 64 . In addition, mutant uromodulin inhibits trafficking and activity of the NKCC2 in the TAL 59 . The resulting defect in urinary concentration and mild volume depletion can subsequently increase the reabsorption of uric acid in the proximal tubule, leading to lower fractional excretion of urate (FE urate ; below 0.05 in most patients) and hyperuricaemia, and to gout in approximately 25-75% of patients with ADTKD-UMOD 65, 66 . Of note, FE urate is lowered in CKD of all causes, so it is not a reliable diagnostic tool in patients with an estimated glomerular filtration rate (GFR) of <80 ml/min/1.73 m 2 (refs 66, 67 ). The early induction of inflammation, preceding the induction of profibrotic signals 68 , seems to have an important role in disease progression. Indeed, blocking Box 2 | Differential diagnosis of ADTKD Several conditions can be considered in the differential diagnosis for autosomal dominant tubulointerstitial disease (ADTKD). The most likely to be implicated are:
• Atypical autosomal dominant polycystic kidney disease with normal-sized cystic kidneys, kidney fibrosis and slowly progressive chronic kidney disease (CKD) due to dominant mutations in DNAJB11 (ref.
13
). Similar characteristics with ADTKD include bland urinary sediment and normal kidneys on ultrasonography at a young age. However, there is a high prevalence of renal cysts in most affected family members.
• tumour necrosis factor (TNF) signalling was shown to reduce apoptosis and proinflammatory and fibrotic signals, and to ameliorate kidney failure 64 . Overall, these in vivo studies establish a main gain-of-function effect of uromodulin mutations, which is also supported by the lack of a renal histological phenotype in Umod-knockout mice (even at old age) 69 .
Phenotype. Regarding correlations between genotype and phenotype, patients with ADTKD-UMOD who harbour a deletion (as opposed to a missense mutation) may have slightly worse renal outcome 66 . The type of missense mutation and the localization of the missense mutation might also negatively influence renal prognosis 70 . Furthermore, rare cases of patients with homozygous UMOD mutations suggest a dose-dependent effect on uromodulin biology and possibly on the clinical presentation 65, 71, 72 , a correlation corroborated in mice 61, 63 . The described inverse correlation between morning urine osmolality and uric acid levels in those with ADTKD-UMOD suggests that the defective TAL function may induce a discrete salt-losing phenotype, with plasma volume contraction and compensation by the proximal tubule, yielding higher reabsorption of urate and hyperuricaemia 67 .
ADTKD-MUC1
Mucin 1 (encoded by MUC1) is a membrane-based apical protein involved in cellular signalling as well as the lubrication and protection of luminal surfaces of epithelia 73 . In the kidney, mucin 1 has a protective role in acute kidney injury models by transactivating the hypoxia-inducible factor 1α (HIF1α) and β-catenin pathways, and has a regulatory effect on calcium balance by stabilizing the TRPV5 calcium channel on the cell surface 74, 75 . Mucin 1 belongs to a group of mucoproteins that are expressed on different epithelial tissues throughout the body. In the kidney, mucin 1 is expressed in the TAL, DCT and collecting ducts 9 . MUC1 has a variable number of tandem repeat (VNTR) regions, with each 60-nucleotide repeat encoding 20 amino acids ( fig. 3 ). Each allele has between 20 and 125 repeats that encode a repetitive sequence of amino acids that is important for the massive O-glycosylation of mucin 1 (ref. Pathogenesis. In the majority of cases of ADTKD-MUC1, a cytosine duplication in a tract of seven cytosine residues results in the addition of a single cytosine residue, leading to a frameshift mutation 9 . The mutation results in the creation of a new frameshift protein termed MUC1fs, which retains the wild-type N-terminal signal sequence of MUC1 that drives ER co-translation translocation. All VNTR segments prior to the mutation have the wild-type MUC1 sequence, but all VNTR segments after the frameshift mutation have a new repetitive sequence of 20 amino acids containing 1 cysteine and 6 basic amino acid residues per mutated VNTR unit. The frameshift mutation terminates the MUC1fs protein synthesis soon after the VNTR, leading to a loss of all C-terminal information needed for post-translational processing, cellular signalling, membrane targeting and recycling of mucin 1. MUC1fs is, therefore, a cysteine-rich protein with an isoelectric point of ~12 that lacks the abundant N-glycosylation and O-glycosylation found in wild-type mucin 1. MUC1fs is predicted to be a highly positively charged and natively unfolded protein. Six types of frameshift mutations that result in ADTKD-MUC1 have been reported, each of them resulting in the abnormal MUC1fs protein 76, 77 . The mutation of MUC1 may occur in any one of the VNTR units. Each individual in the family has a 50% chance of inheriting the affected allele, which will always have the mutation occurring in the same VNTR as other family members 78 . The particular frameshift mutation is thought to be central to the pathogenesis of ADTKD-MUC1 as Muc1-knockout mice do not have kidney abnormalities 79 and all mutations leading to ADTKD express the MUC1fs protein 9, 77, [80] [81] [82] [83] [84] . No mutations have so far been identified that result in truncation , and is modulated by the activity of the calciumsensing receptor (CaSR) operating at the basolateral side of TAL cells 155 . Immunogold labelling studies have shown that uromodulin is present in vesicles close to the basement membrane of TAL cells 37 . However, the mechanism by which a small fraction of the produced uromodulin is targeted to the basolateral membrane and then to the blood remains unknown. Proteolytic cleavage is required for monomeric uromodulin to assemble into high molecular weight polymeric filaments forming a dense matrix in the urine. Such a matrix is probably required for the protective function of uromodulin against urinary tract pathogens and renal stone formation. b | The predicted structure of uromodulin contains a leader peptide (L), four epidermal growth factor (EGF)-like domains (I-IV; whereby EGF-II and EGF-III are predicted to be Ca 2+ binding), a cysteinerich domain (D8C) and a bipartite C-terminal Zona Pellucida domain (ZP_N and ZP_C). The position of glycosylphosphatidylinositol anchoring (predicted at position 614) and the seven N-glycosylation sites (triangles) are indicated 34 . Part a adapted with permission from ref.
156
, Elsevier.
or deletion of wild-type mucin 1. Immunohistochemical studies have shown deposition of MUC1fs in many different epithelial cell types, including the kidney, stomach, breast, sebaceous glands and urinary cells, but clinical sequelae only seem to occur in the kidneys for reasons that are unclear 9, 77, 80, 82, 84 . One hypothesis to explain the kidney-specific manifestations is that MUC1fs interacts specifically with another protein present only in kidney tubular cells, causing local damage.
The accumulation of MUC1fs may also be promoted by the lower turnover of tubular cells, which have a reduced capacity of regeneration in the adult kidney 85 .
ADTKD-HNF1B
HNF1B encodes the transcription factor HNF1β. Mutations in HNF1B comprise missense, non-sense, frameshift and splice site mutations; in >50% of patients with ADTKD-HNF1B, whole-gene deletions of exons 1-9 are evident. In ~50% of cases mutations are de novo; in all other cases the segregation follows a dominant inheri tance pattern 11, 86, 87 . In some cohorts, a preponderance of maternal inheritance is observed, suggesting imprinting mechanisms or reduced fertility in males 88 .
Function. HNF1β is widely expressed in fetal tissues, but its role in early kidney development has not been completely elucidated. HNF1β seems to have a role in ureteric bud branching and in mesenchymal-epithelial transition, altering WNT signalling. Its transactivation potential depends on normal DNA-binding activity and the recruitment of co-activator proteins such as CREB-binding protein (CBP) and p300/CBP associated factor (PCAF) 89 . Inactivation of Hnf1b in the mouse metanephric mesenchyme leads to a drastic tubular defect, with nephrons having glomeruli directly connected to collecting ducts via a short tubule, in the absence of proximal, distal and loop of Henle segments 90 . The complete knockout of Hnf1b in mice is lethal, whereas kidney-specific inactivation results in polycystic kidney disease 91 . Furthermore, HNF1β has been shown to regulate a co-activator of the transcription factor peroxisome proliferator-activated receptor-γ (PPARγ), which controls mitochondrial biogenesis and function, suggesting that a mitochondrial component could play a part in ADTKD in general (see below) 17, 97 . The broad phenotypic variability of ADTKD-HNF1B may also involve specific timeframes of HNF1β activity during organogenesis and/or the influence of modifier genes 91, [98] [99] [100] [101] . Importantly, deletion of HNF1B may be part of the 17q12 deletion syndrome, as the 1.5 MB chr17q12 microdeletion includes HNF1B as well as 14 other genes 102, 103 . The syndrome is characterized by variable combinations of kidney and urinary tract abnormalities, maturity-onset diabetes of the young type 5 (MODY5), and neurodevelopmental or neuropsychiatric dis orders (for example, developmental delay, autism spectrum dis order, attention deficit/hyperactivity disorder, schizophrenia and bipolar disorder) [104] [105] [106] . Since the deletion , which is important for extensive O-glycosylation, and C-terminal cytoplasmic β subunits that anchor mucin 1 to the cytoskeleton (this hypothetical interaction with the cytoskeleton is indicated with a question mark). The extracellular domain is involved in the lubrication and protection of luminal epithelial surfaces and the intracellular domain is involved in signalling through phosphorylation and protein-protein interactions 73 . c | The predicted structure of wildtype mucin 1 (top) contains the signal peptide (SP) that drives co-translational translocation in the endoplasmic reticulum, the VNTR region, a sperm protein, enterokinase and agrin (SEA) domain within which an auto-proteolytic cleavage into the N-terminal extracellular α subunit and C-terminal cytoplasmic β subunit forms a heterodimeric mucin 1 complex, and a hydrophobic transmembrane (TM) domain that embeds mucin 1 into the plasma membrane of epithelial cells. The mutated protein, MUC1fs (bottom), contains the SP, part of the wild-type VNTR and a new VNTR segment (green boxes) after the frameshift mutation (triangle). MUC1fs lacks all C-terminal information needed for posttranslational processing, cellular signalling, membrane targeting and recycling of mucin 1. Part b adapted with permission from ref. contains 15 genes, the genetic mechanism that causes the observed neurodevelopmental manifestations remains to be defined. With the exception of neuropsychological symptoms in patients with chr17q12 deletion syndrome, genotype-phenotype correlations could not be established in most studies 20, 88, 107 . One study, including 201 adult patients, described a lower incidence of severe CKD in patients with HNF1B deletions than in patients with HNF1B mutations 108 . With respect to tubulointerstitial disease, both truncating mutations and whole-gene deletions have been described in ADTKD-HNF1B 20, 88 .
ADTKD-REN
REN encodes preprorenin, a precursor of prorenin and renin. Renin is an aspartic protease produced and secreted by the juxtaglomerular cells, which are specialized, granular vascular smooth muscle cells mainly in the afferent arterioles. Renin participates in the reninangiotensin-aldosterone system (RAAS), which has widespread roles, including in nephrogenesis, blood pressure control, modulation of erythropoiesis and regulation of thirst. Renin functions through local renin-angiotensin systems in many organs ( fig. 5 ).
Pathogenesis. ADTKD-REN is characterized by anaemia occurring within the first year of life and slowly progressive CKD. Mild hyperkalaemia and mild hypotension may also occur due to hyporeninaemic hypoaldosteronism. Hypoproliferative anaemia is associated with low serum erythropoietin levels and is erythropoietin responsive 10 . Anaemia in ADTKD-REN resembles that observed in haemodialysis and transplant patients receiving long-term angiotensin converting enzyme (ACE) inhibition, as the RAAS contributes to erythro poietin production 109 . Anaemia in ADTKD-REN resolves during puberty, likely due to the increased sex steroid production that also increases erythropoietin production ) results in vascular hypertrophy, focal tubular atrophy and interstitial inflammation 110 . In humans, homozygous loss-offunction REN mutations that result in the complete absence of renin production cause autosomal recessive renal tubular dysgenesis 111 . This heterogeneous dis order of renal development is usually lethal; in rare survivors, it is associated with refractory low blood pressure. By contrast, in ADTKD-REN, production of wildtype renin occurs via one allele, which enables kidney development. In vitro transfection studies of ADTKD-REN mutations -affecting the signal sequencedemonstrated impaired ER translocation and processing of preprorenin, resulting in deficient prorenin and renin secretion. Stable cell lines expressing p.Leu16del preprorenin showed activated ER stress and UPR, confirmed by the presence of spliced x-box protein 1 (XBP1) 10 .
ADTKD-SEC61A1
After exclusion of known genes, two families with ADTKD have been linked to heterozygous, loss-offunction mutations in SEC61A1 (ref.
12
). SEC61A1 encodes the α1 subunit of the transport protein SEC61 (SEC61α), which is part of the heterotrimeric protein-conducting channel SEC61 (together with SEC61 subunit-β (SEC61β) and SEC61 subunit-γ (SEC61γ)). SEC61 is part of the ER translocon needed to transport newly synthesized secretory proteins into the ER 112 . Mutations in SEC61A1 that cause ADTKD-SEC61A1 (namely, p.Thr185Ala and p.Val67Gly) disrupt the function of the translocon pore by affecting the integrity of the plug domain or the constriction ring (fig. 6 ). These structural alterations lead to aggregation of mutated SEC61α in the ER and partial mislocalization of mutant peptides to the Golgi and ER-Golgi intermediate compartment 12 , and may destabilize the translocon pore, leading to altered post-translational modifications, folding and sorting of various secretory and transmembrane proteins. Affected proteins include uromodulin, mucin 1 and renin. Other effects of SEC61α mutation include alterations in Ca 2+ homeostasis and energy metabolism 113 . Such dysfunctions may induce or prevent the cell from responding appropriately to ER stress, ultimately leading to apoptosis and tissue damage. Indeed, the potential link between ER stress and ADTKD is further supported by the recent identification of heterozygous mutations in DNAJB11 in seven families presenting with non-enlarged cystic kidneys and progressive interstitial fibrosis resulting in late-onset ESRD 13 . DNAJB11 encodes a cofactor of binding immunoglobulin protein (BIP), which is a key chaperone of the ER quality control mechanism 114 . The partial overlap of the phenotype of these families with ADTKD and the evidence of a strong intracellular staining for uromodulin (and possibly mucin 1) observed in two kidney biopsies suggest that the loss-of-function of DNAJB11 may impair ER processing and maturation of key proteins, resembling the cellular phenotype attributable to mutations in SEC61A1 and UMOD (fig. 7) . REN) is caused by dominant mutations in the SP sequence of preprorenin affecting synthesis, glycosylation and secretion of prorenin and mature renin. In the short term, the mutations lead to hyporeninaemic hypoaldosteronism and anaemia. In the long term, the expression of the mutated protein is thought to cause endoplasmic reticulum stress, which affects the viability of juxtaglomerular cells and causes a slowly progressive tubular atrophy, glomerular scarring and interstitial fibrosis. ACE, angiotensin converting enzyme.
Diagnosis, screening and prevention
of ADTKD. In such families, genetic testing should be considered in a member with CKD to establish a diagnosis for the affected individual and family (Box 3).
A diagnostic dilemma occurs in individuals with CKD with a bland urinary sediment but without a family history. Whilst kidney biopsy is important to exclude other treatable causes of tubulointerstitial kidney disease (such as tubulointerstitial nephritis), it is not possible to make a diagnosis of ADTKD based solely on biopsy findings. Indeed, a primary genetic diagnostic approach may provide the diagnosis of ADTKD and would make a kidney biopsy unnecessary. At this time, genetic testing remains expensive, difficult to perform (in particular for evaluation of MUC1 mutations) and unlikely to be positive given the rarity of ADTKD. Moreover, as long as no specific treatments for ADTKD are available, genetic testing is not compulsory (Box 3). Thus, in many cases, a genetic diagnosis of ADTKD may not be made. Given this scenario, it is important to carefully rule out other causes of tubulointerstitial disease such as tubulointerstitial nephritis, uveitis, proton pump inhibitor-associated kidney disease and Sjögren syndrome ( fig. 8 ).
Clinical characteristics
The usual clinical findings in ADTKD are a progressive loss of kidney function with bland urinary sediment, absent-to-mild albuminuria, proteinuria and haematuria, urinary concentrating defects with low morning urine osmolality, and a family history of CKD that is compatible with an autosomal dominant inheritance pattern. Considerable interfamilial and intrafamilial variability has been observed in CKD progression among individuals with ADTKD. The rate of decline of GFR, usually assessed by estimated GFR, is highly variable in ADTKD-UMOD 66 , ADTKD-MUC1 (ref.
80
), ADTKD-REN and ADTKD-HNF1B 21 . On imaging studies, the kidneys are normal or small in size, in contrast with the typically enlarged polycystic kidneys in ADPKD. Renal cysts can occur but are not typical for the disease. The histology shows atypical findings of interstitial fibrosis and tubular atrophy with a thickening and lamellation of tubular membranes and occasionally microcystic dilatations. Specific features of each subtype of ADTKD may also be present (TaBle 2) .
ADTKD-UMOD.
Early gout (with respect to patient age and kidney function) with a reduced FE urate is typically encountered in those with ADTKD-UMOD. Analysis of a cohort of French and Belgian patients with ADTKD-UMOD (n = 109 from 45 families) showed that ~90% of the individuals had a dominant family history of gout or CKD. Hyperuricaemia was prevalent (71% of patients >75th percentile, corrected for GFR), especially in women, and FE urate was reduced 66 . Gout was present in 50% of women and 75% of men, and had an early onset (median age 21 years). Mean age at onset of ESRD ranged from 25 years to >70 years (median 54 years), with considerable intrafamilial variability. Men deve loped gout and kidney failure earlier than women (age at ESRD 50 years for men versus 60 years for women) 70 . A mildly increased incidence of enuresis (involuntary urination, especially at night) was noted in children with ADTKD-UMOD 115 . When comparing patients with ADTKD-UMOD with patients with ADTKD in whom no UMOD mutation was detected, mutations in UMOD seem to be associated with an earlier age at presentation and a higher prevalence of gout 2, 66 . This observation may prompt clinical suspicion of ADTKD-UMOD 1 .
ADTKD-MUC1. The cardinal features of ADTKD-
MUC1 are dominant inheritance and slowly progressive CKD, without other typical clinical findings 66, 80 . Patients have a variable rate of progression to ESRD and can show, although less consistently than in ADTKD-UMOD, hyperuricemia and gout. A Spanish retrospective cohort study compared 9 families with ADTKD-UMOD and 16 families with ADTKD-MUC1, showing earlier age at diagnosis in those with ADTKD-UMOD than in those with ADTKD-MUC1 (32.4 years versus 40.8 years; P = 0.03) 65 . The earlier age of diagnosis of ADTKD-UMOD is likely due to the higher prevalence of gout, which leads to testing of kidney function and findings of CKD. The median age at onset of ESRD was similar (51 years for ADTKD-MUC1 versus 56 years for ADTKD-UMOD; P = 0.10), with similar slopes in estimated GFR decline (-3 ml/min/1.73 m 2 for ADTKD-UMOD and -3.9 ml/min/1.73 m 2 for ADTKD-MUC1; P = 0.20) 65 . Hyperuricaemia was more frequent in ADTKD-UMOD than in ADTKD-MUC1 (87% versus 54%, respectively; P = 0.006) and gout was slightly more prevalent (24% versus 7%, respectively; P = 0.07). Except for gout, no extrarenal manifestations were encountered in either ADTKD-UMOD or ADTKD-MUC1.
ADTKD-HNF1B. Mutations in HNF1B
are associated with a range of renal and extra-renal diseases 11 ( fig. 4b) and, in severe cases, ADTKD-HNF1B can manifest prenatally [116] [117] [118] . HNF1B mutations have also been identified in paediatric patients with isolated renal disease 99, 107 . A typical presentation of antenatal HNF1B nephropathy is bilateral hyperechogenic kidneys of enlarged to normal size on ultrasonography; in some of these patients, renal cysts can be observed after birth 116 . With the exception of very early onset cases associated with ESRD, HNF1B nephropathy has a favourable course in childhood, with a mean annual GFR decline of -1.0 ml/min/1.73 m 2 (ref.
88
). During adulthood, loss of renal function seems to accelerate, as suggested in a series of 27 adult patients with ADTKD-HNF1B with an annual GFR reduction of -2.45 ml/min/1.73 m 2 (ref.
21
).
Hyperuricaemia was documented in 37% of paediatric patients with an early onset of 1 year of age 88 and in 20% of adult patients 119 . Among patients with kidney dysplasia, hyperuricaemia disproportionate to renal function highly suggests ADTKD-HNF1B nephropathy as the underlying cause 28 .
Renal magnesium wasting in ADTKD-HNF1B
93 is thought to occur, at least in part, due to the regulation of the transcription of FXYD2, the γ-subunit of the Na + /K + -ATPase, by HNF1β in the distal tubule 120 . FXYD2 is suggested to be important for maintaining the function of the Na + /K + -ATPase in the DCT, which in turn controls the membrane potential at the apical membrane and the driving force for transcellular Mg 2+ uptake 121 . Hypomagnesaemia (<0.75 mmol/l) was reported in 63% of patients with ADTKD-HNF1B, with a median age of 35 years 21 ; in paediatric patients, lower rates (24%) of hypomagnesaemia (<0.65 mmol/l) were observed 88 . Besides differences in cut-off values for hypomagnesaemia by age, the development of this condition seems to be age related.
The same holds true for hyperglycaemia, elevated glycated haemoglobin levels (a marker of long-term blood glycaemic control) or both. Impaired glucose tolerance and diabetes mellitus are rarely observed in childhood but seem to develop later in the course of ADTKD-HNF1B. During biosynthesis, uromodulin, mucin 1 and renin, which are glycosylated secretory proteins expressed in the kidney, need to be co-translationally translocated into the endoplasmic reticulum (ER). This process is initiated in the cytoplasm by interaction of the signal sequence of the nascent protein with the signal recognition particle (SRP) and proceeds further via interaction of the protein translating complex with SRP receptor and SEC61 complex, which is a membrane channel through which the protein is transferred into the ER lumen. In the ER, the nascent protein undergoes a series of modifications including removal of the signal peptide by signal peptidase, N-glycosylation, disulfide bond formation, and oxidoreductase-mediated and chaperone-mediated folding. Properly modified and folded proteins then exit the ER and enter the Golgi and secretory pathway. Abnormalities in this process induce ER stress and the unfolded protein response. For example, in the UMOD subtype of autosomal dominant tubulointerstitial kidney disease (ADTKD-UMOD), mutations affect uromodulin folding and mutant protein accumulates in the ER lumen. In ADTKD-MUC1, the frameshift mutations lead to production of an abnormal MUC1fs protein in the ER and to its retention along the secretory pathway. In ADTKD-REN, mutations in the signal peptide impair ER translocation and processing of preprorenin and result in deficient prorenin and renin secretion. In ADTKD-SEC61A1, mutations affect the integrity of the plug domain or the constriction ring to disrupt translocon pore function, leading to aggregation of mutated SEC61α in the ER and partial mislocalization of mutant SEC61α to the Golgi and ER-Golgi intermediate compartment. This abnormal translocon function affects production of many proteins, potentially including uromodulin, mucin 1 and renin. The potential link between ER stress and ADTKD is supported by the recent identification of heterozygous mutations in DNAJB11 (ref.
13
), a key chaperone of the ER quality control mechanism. RER, rough endoplasmic reticulum.
However, under certain circumstances (for example, after kidney transplantation with concomitant high doses of steroids, tacrolimus or both), diabetes mellitus may be revealed in patients with ADTKD-HNF1B
122
, requiring specific treatment and often a change in the immunosuppressive regimen. As new-onset diabetes after transplantation is a serious complication compromising renal graft function 123 , screening for HNF1B mutations should be considered before transplantation in patients with ESRD caused by (cystic) kidney dysplasia.
Neonatal cholestasis, elevated liver enzyme activity and genital tract anomalies resulting from Müllerian duct aplasia and failure of fusion of the Müllerian ducts have been described with varying frequency in patients with HNF1B mutations 21, 124, 125 . If genital tract malformations are combined with renal abnormalities, HNF1B muta tion analysis seems to be warranted 126 . Neuropsychological symptoms, including autism spectrum disorders, have been described in patients with 17q12 deletion syndrome 104, 105 .
ADTKD-REN.
The clinical sequelae of ADTKD-REN are related to a relative decrease in renin as well as likely accumu lation of the mutated renin protein 10, 30 . A nearly uni versal manifestation is the presence of anaemia early in childhood that is characterized by low erythropoietin levels. Indeed, congenital anaemia has been reported in ADTKD-REN 10, [30] [31] [32] , with haemoglobin concentrations in the range of 7-11 mg/dl; some children remain asymp tomatic and do not require erythropoietin treatment. Haemoglobin returns to the normal range with adolescence and then begins to decline with CKD later in life. Patients may also have mild hypotension and mild hyper kalaemia that is responsive to fludrocortisone. Some patients may manifest polyuria. Hyperuricaemia and gout are frequent. Similar to patients receiving ACE inhibitors, affected children from infancy onwards are at risk of acute kidney failure when volume-depleted and/or receiving non-steroidal agents. As with other forms of ADTKD, CKD worsens over time, with the need for renal replacement therapy between the ages of 30 years and 70 years.
ADTKD-SEC61A1. Two families have been described to have mutations in SEC61A1 (ref.
12
). One family included individuals with congenital anaemia and intrauterine and postnatal growth retardation. Other findings included a cleft palate, bifid uvula, pre-axial polydactyly and mild cognitive impairment. The other family included individuals with congenital anaemia and neutropenia and with recurrent cutaneous abscess formation during childhood 12 . Affected members also had gout. Growth and cognitive development were normal in this family.
Diagnostic work up
Pathological features. When performed, kidney bio psies reveal tubulointerstitial scarring with secondary glomerulosclerosis. Sometimes patients are erroneously diagnosed with primary focal and segmental glomerulosclerosis. Thickening and lamellation of tubular basement membranes and rare tubular dilations have been described 5, 127 . Although immunofluorescence examination for uromodulin is not routinely performed, it can detect the abnormal accumulation of (mutant) uromodulin within the TAL segment 5, 6, 48 . The intracellular accumulation of uromodulin is also reflected by a substantially decreased uromodulin concentration in the urine of affected individuals, irrespective of the degree of kidney failure 5, 53 . Although these assays should be further validated and standardized, the detection of very low levels of uromodulin in urine and plasma offers a perspective for non-invasive testing 5, 53, 72 . The presence of the MUC1fs protein in urinary cells enabled the development of an immunocytochemical test to diagnose ADTKD-MUC1 (ref.
76
). This method can also be used to detect MUC1fs in intracytoplasmic granules in kidney biopsies. Positive MUC1fs staining has also been detected in the skin (sebaceous glands) and breast ducts of affected individuals 76 . The potential value of immunostaining for MUC1fs in human kidney biopsies to identify patients with ADTKD-MUC1 was substantiated by unbiased tissue array screening 84 . However, immunostaining of tissues with anti-MUC1fs antibodies can be difficult and imprecise owing to non-standardized techniques. Urinary staining for the MUC1fs protein is an attractive alternative. As mucin 1 is produced by bladder cells, staining can even be performed on the urine of patients who have undergone kidney transplantation. A few reports have described decreased immunostaining for renin in the juxtaglomerular apparatus in patients with ADTKD-REN 10, 30 . No other specific pathological features have been reported for other subtypes.
Imaging. Kidney ultrasonography in patients with ADTKD-UMOD, ADTKD-MUC1 and ADTKD-REN is non-diagnostic, with normal or small kidneys (depending on CKD stage). In contrast, ADTKD-HNF1B is ante natally suspected in the presence of hyperechogenic, large to normal kidneys on ultrasonography and is an important differential diagnosis to autosomal recessive polycystic kidney disease. In infancy and childhood, bilateral cystic kidney dysplasia has a high risk of being caused by HNF1B mutations -with a mutation detection rate of 20-30% in these cases 107 . Glomerulocystic
Box 3 | Ethics and implications of genetic testing in ADTKD
There are several advantages for obtaining a genetic diagnosis for a family with autosomal dominant tubulointerstitial disease (ADTKD). For example, owing to the autosomal dominant inheritance, kidney disease often has affected many family members for generations; thus, both affected and unaffected family members may strongly desire a diagnosis. Additionally, achieving a diagnosis will preclude more invasive testing such as kidney biopsy and further futile or costly biological testing. Identification of ADTKD as a cause of disease enables one to predict a slow progressive loss of kidney function over time. Without a diagnosis, the rate of decline cannot be predicted and may require closer follow-up. Family planning may be affected considerably by diagnosis. Asymptomatic family members can be screened as potential kidney donors. However, disadvantages to family testing include the fact that one family member will receive a certain genetic diagnosis of ADTKD that could affect their ability to obtain health insurance or life insurance in some countries. Thus, testing a family member who already has advanced kidney disease might be preferable. Dependent on ethical standards in different countries, pre-implantation diagnosis is not necessarily justified for ADTKD given the late age of onset and available treatments for end-stage renal disease. The nature of the gene involved and the possibility for extrarenal manifestations should also be taken into account in such discussions 152, 153 .
12 | Article citation ID: kidney and renal dysplasia dominate the microscopic features of fetal ADTKD-HNF1B nephropathy 128 . HNF1B-specific extrarenal symptoms and hyperuricaemia disproportionate to the degree of CKD can also aid in the diagnosis of ADTKD-HNF1B Autosomal dominant tubulointerstitial kidney disease (ADTKD) should be considered once the presence of tubulointerstitial kidney disease has been ascertained (by biopsy) or is suspected on the basis of imaging and/or clinical findings (such as bland sediment, mildly elevated albuminuria and mildly elevated blood pressure) and if the family history is compatible with a dominant inheritance pattern. The lack of a family history does not exclude the diagnosis of ADTKD, which will require genetic testing. One should ascertain, through family members, if a genetic diagnosis has been obtained in any individuals. Although de novo mutations are possible, they are rare in the genes implicated in ADTKD, except for HNF1B. Testing for de novo mutations in individuals without a family history should likely be reserved for younger individuals who have unexplained causes of chronic kidney disease (CKD); these individuals should undergo genetic testing for nephronophthisisrelated ciliopathies. The methodology for genetic testing is evolving rapidly, reflecting the development of next-generation sequencing (NGS) and panels. NGS has proven a powerful tool to detect monogenic mutations in patients with CKD, including mutations in UMOD, HNF1B, REN and SEC61A1 (ref.
3 ). However, mutations in MUC1 may be missed when whole-exome sequencing is performed owing to the repetitive nature and high guanosine and cytosine content of the variable-number tandem repeats. Deletions of HNF1B require specific assays such as multiplex ligation-dependent probe amplification (MLPA) or copy number variation (CNV) analysis. These limitations should be kept in mind when using NGS to decipher ADTKD. The interpretation of the genetic findings may be guided by some clinical and laboratory findings. If there is a history of gout or hyperuricaemia prior to the development of CKD, one should first consider the UMOD (frequent association) and MUC1 (less frequent association) genes. If both UMOD and MUC1 genetic testing are negative, genetic linkage to 1q22 or immunostaining for the mutant MUC1fs protein in urine may suggest a tentative diagnosis of ADTKD-MUC1. ADTKD-UMOD and ADTKD-MUC1 are by far the most prevalent genetic entities. Mild hypo tension and anaemia during childhood have been associated with REN mutations. Syndromic features and various kidney abnormalities have been reported in individuals with mutations in HNF1B. Intrauterine growth retardation, congenital anaemia, neutropenia, hypogammaglobulinaemia or recurrent infections can be attributed to mutations in SEC61A1. NGS may reveal new genes associated with ADTKD, as a substantial number of cases do not show mutations in these genes. +, positive result; -, negative result; ADPKD, autosomal dominant polycystic kidney disease; FE urate , fractional excretion of urate; MS, mass spectrometry. Adapted from ref. before undertaking genetic testing (Box 3). Physicians also need to be cognizant of the fact that many individuals desire a genetic diagnosis, even if a treatment is not available. A genetic diagnosis avoids unneeded, potentially costly or invasive procedures, provides information about prognosis, and allows early evaluation for kidney transplantation with identification of family members as donors. Importantly, as not all patho genetic mutations and genes have yet been identified -and because mutations in MUC1 cannot be detected with current gene panels -negative genetic testing does not exclude the diagnosis of ADTKD. Of note, the causative role of genetic variants needs to be supported by in silico and, potentially, functional studies, as recommended 129 . Distinct technical approaches are necessary to identify ADTKD-causing mutations, including standard Sanger and next-generation sequencing (NGS) for UMOD, REN, HNF1B and SEC61A1, multiplex ligation-dependent probe amplification (MLPA) for HNF1B, and targeted mutation analysis for MUC1. For individuals who do not have a family history of autosomal dominant kidney disease, the possibility of a de novo mutation in HNF1B or a recessive mutation in one of the genes involved in nephronophthisis-related ciliopathies should be considered 130 ( fig. 8 ).
Although ~90% of mutations in UMOD occur in exons 3 and 4, the genetics laboratory should sequence all 11 exons of the gene to capture 100% of the possible mutations. Once a family member is identified as having ADTKD-UMOD, testing of other family members may be considered. Testing may be helpful for future family planning, to check for potential kidney donors or to ascertain the cause of CKD. In general, genetic testing of asymptomatic children for conditions in which there are no specific treatment is discouraged 131 . Testing of children may be considered in families with a high prevalence of gout and initiation of allopurinol to prevent gout may be considered. It should be emphasized that some indivi duals in their third and fourth decade of life with 'normal' kidney function may be found to have ADTKD-UMOD. The decision of testing such individuals should be weighed against the fact that there are currently no available treatments slowing disease progression.
Owing to the complexities of the genetic structure and the high guanosine-cytosine content, MUC1 mutations cannot be routinely identified through conventional Sanger sequencing or NGS. The difficulty lies in identifying a cytosine duplication (or any other frameshift mutation) within one of the 20-250 repeat units of the VNTR in the open reading frame of MUC1. The sequence analysis is further complicated by the size of the VNTR, which ranges from 1.5 kb to 7.5 kb, and by its sequence, which is >80% GC rich. Thus, there is no reference sequence of the VNTR available and knowledge on its population diversity is limited. Furthermore, the cytosine duplication is family-specific, occurring in a different unit of the repeat in each family 9 . Mutational analysis for the most common mutation (cytosine duplication) for ADTKD-MUC1 is available from the Broad Institute and a few academic centres in Europe. Furthermore, ADTKD-MUC1 testing, at present, only identifies the cytosine duplication: there are other mutations that cause the same frameshift mutation that cannot currently be sequenced easily 76 . Thus, to date, a negative mutational analysis for MUC1 does not rule out this diagnosis. In (large) families that test negative for the MUC1 cytosine duplication and a UMOD mutation, genetic linkage may be performed to seek potential linkage to the MUC1 locus at 1q22. Immunostaining of tissues or urinary cell smears for the MUC1fs protein may also be performed 76, 84 . In cases with positive immunohistochemical staining for MUC1fs, Illumina sequencing and specific bioinformatic analysis of the MUC1 genomic region may reveal other types of frameshift mutations 76 . For families using in vitro fertilization for reproduction, preimplantation diagnosis for ADTKD-MUC1 remains an ethical (Box 3) and technical challenge but may, in some cases, be achieved using short tandem repeat genotyping.
For the diagnosis of ADTKD-HNF1B, conventional sequencing for intragenic mutations has to be combined with specific assays to identify whole-gene deletions such as MLPA or copy number variation (CNV) analysis 132 . The 17q12 deletion, which encompasses HNF1B and 14 additional genes, is identified by chromosomal microarray analysis or by comprehensive genomic testing, including CNV detection methods 106 . De novo mutations are observed in 40% of patients with a preponderance of deletions 20, 88 ; in these patients, upstream generations are unaffected. However, patients with de novo mutations will, statistically, transmit the mutation to 50% of their offspring following the dominant mode of inheri tance of ADTKD. Thus, genetic counselling should be offered to all mutation carriers (Box 3).
ADTKD-REN, ADTKD-SEC61A1 and mutations in DNAJB11 are mostly caused by pathogenic single nucleotide variants. Standard methods of genetic testing, including Sanger sequencing and NGS sequencing, may, therefore, be used.
Management
There is no current treatment for ADTKD-UMOD and ADTKD-MUC1 except for general measures for CKD. By contrast, children with ADTKD-HNF1B and ADTKD-REN disease are likely to benefit from early management by a paediatric nephrologist 1 . Individuals affected with ADTKD should be treated according to established CKD guidelines 133 . These guidelines elaborate on the management of progression and complications of CKD, including blood pressure control, blockade of the RAAS, protein intake, lifestyle modifications, hyperuricaemia, anaemia, metabolic bone disease, acidosis, electrolyte abnormalities, cardiovascular disease, risk of infection and acute kidney injury. Due to the low prevalence of ADTKD, specific recommendations are based on limited evidence. For example, no data substantiate the effect of ACE inhibitors or angiotensin receptor blockers on CKD progression in patients with ADTKD, who are usually normotensive. If a decision is made to prescribe an angiotensin receptor blocker, patients with hyperuricaemia (who do not have ADTKD-REN) should be treated with losartan, as it lowers serum urate levels through increased urinary urate excretion 134 . Diuretics should be used with caution in patients with ADTKD, as these drugs may aggravate salt loss, volume depletion and hyperuricaemia 135 . A low-salt diet is not recommended for the same reasons. Water intake ad libitum is advised to compensate for urinary concentration defects. NSAIDs should be avoided in all patients with ADTKD, with a particular risk of acute kidney injury in patients with REN mutations 1, 10, 30 . Once patients with ADTKD-UMOD and ADTKD-REN develop gout, there is a high risk of future gout attacks and tophus development that can be prevented with treatment with allopurinol or another urate-lowering medication 66, 136 . Whether treatment with allopurinol -or a low purine diet -might slow progression of CKD remains a matter of debate 137, 138 . The morbidity of ADTKD-HNF1B is strongly related to the degree of kidney dysplasia and impaired renal function. If oligoamnios or anhydramnios (that is, low or no amniotic fluid) and pulmonary hypoplasia are present at birth, the prognosis can be severe or even lethal. Neonatal dialysis might be necessary in exceptional cases, followed by kidney transplantation at later ages. Aside from these early-onset cases of ESRD in childhood, HNF1B nephropathy has a slow progressive course 88 . The clinical management is symptomatic, targeting the effects of CKD on vitamin D and bone metabolism, renal anaemia, arterial hypertension, growth retardation, hypomagnesaemia, hyperuricaemia, endocrine and exocrine pancreatic dysfunction, and in special cases, symptoms of genital tract malformations, which might require restorative surgery. Ongoing studies aim at identifying patients with ADTKD-HNF1B who are prone to autism spectrum disorders or development of other neuropsychological symptoms that need specific treatment 28 . Anaemia and hypotension as well as hyperkalaemia associated with ADTKD-REN can be treated with erythropoiesis-stimulating agents and fludrocortisone, respectively 10, 30 .
ESRD
Kidney transplantation is the preferred option for patients with ESRD due to ADTKD 139 . Given the genetic nature of the disease, ADTKD does not recur in the renal transplant. The rate of loss of kidney function is slow in most patients with ADTKD and unaffected family members may be able to serve as living kidney donors. However, genetic testing should be mandatory for potential kidney donors in affected families 1 . Ideally, patients with ADTKD receive pre-emptive transplantation prior to the need for dialysis. Patients with ADTKD-HNF1B require special attention as they are prone to developing new-onset diabetes after transplantation 122, 140 . This risk is higher with tacrolimus-based immunosuppression regimens and high doses of steroids post-transplantation. Alternative immunosuppressive agents, such as mTOR inhibitors, and a steroid-sparing regimen might be advised in these patients 123 .
Counselling
Like in any dominant disease, genetic counselling should be offered to all affected patients with ADTKD, with emphasis on the 50% risk of passing the disease to their children (Box 3). Potentially affected family members should be informed on risk factors related to CKD (such as hypertension, obesity, medications and smoking) and undergo regular testing of blood pressure and kidney function. It should be noted that the attitude in at-risk individuals should depend on the gene suspected to cause the disease in the family (that is, mutations in genes causing extra-renal or more severe manifestations, for example, HNF1B and REN) and on individual preferences.
Quality of life
The quality of life (QOL) in patients with ADTKD largely depends on the severity of CKD, the presence of CKD-associated comorbidities and the existence of extrarenal manifestations. The evaluation of QOL should comprise aspects of general health, vitality, physical, social and emotional functioning, pain, and mental health (including depressive affect and perception of disease burden). Several studies have demonstrated lower QOL in patients with CKD compared with the general population, influenced by older age, lower socioeconomic status and lower educational level 141, 142 . QOL may also be influenced by the awareness of a hereditable disease and questions of guilt for passing the disease unknowingly to one's offspring. Professional genetic counselling is important to provide information, diagnostic certainty and aid 143 . QOL can be negatively influenced by prominent extrarenal manifestations such as symptomatic anaemia in ADTKD-REN and hypomagnesaemia, diabetes and/or neuropsychological symptoms in ADTKD-HNF1B (fig. 4) . A major impact is reduced fertility in patients with ADTKD-HNF1B and associated genital malformations.
As ADTKD is transmitted as a dominant disorder, the condition has marked effects on QOL for all family members, even those who are genetically unaffected. Many affected individuals may believe they will have a similar experience to their older relatives who experienced transplantation or dialysis at a time when these modalities were not optimized, being unaware of marked improvements in the contemporary era. Affected parents may have experienced long-term disability and/or unemployment, leading to marked financial and emotional effects. Thus, anxiety is a major issue in patients and families with ADTKD. Measures to treat this anxiety include patient education about the disease and the genes involved (Box 4); information about improvements in renal replacement therapy and possibility of pre-emptive transplantation without dialysis; confirmation that patients with ADTKD are optimal kidney transplant candidates, as they have a disease that essentially affects the kidney and will not recur post-transplant; mention of the current research efforts and perspectives in terms of kidney transplantation and development of specific medications or genetic treatments; and psychological support in general. Patients should also be reminded that home remedies or unproven therapies have no confirmed benefit and may be harmful, particularly for affected children 1 .
Outlook
The adoption of the ADTKD-subtype terminology and of diagnostic criteria 1 led to increased awareness and detection of ADTKD and development of webbased resources (Box 4). In turn, the recruitment of an increased number of cases stimulated observational and mechanistic research in the field. Although it was virtually undiagnosed prior to 2000, today, ADTKD is a major cause of monogenic kidney disease. The current efforts in ADTKD are aimed at improved diagnostics, patient involvement and empowerment, development of therapies, better understanding of mechanisms, and implications for other forms of CKD associated with tubulointerstitial fibrosis.
Patients with ADTKD often experience lack of or delays in diagnosis due to the non-specific features of the condition. Individuals are also confronted with a family burden of kidney failure and a 50% chance of passing the disease to their children, often before their own diagnosis has been established. Patients frequently undergo unnecessary and inconclusive diagnostic tests, including invasive kidney biopsies. To solve these problems, alternative diagnostic strategies (such as measurement of uromodulin levels or immunohistochemical detection of MUC1fs) are emerging, with the aim of developing a clinically approved urinary tests. In those with an established diagnosis, insufficient support is often given, with the majority of health-care professionals being unfamiliar with the disease and no specific patient organization available to provide support. Furthermore, the lack of international registries limits the availability of information about the natural course and the phenotypical range of ADTKD, the development of biomarkers of disease progression and the design of future clinical trials.
The genetic epidemiology of ADTKD remains obscure and no clear genotype-phenotype correlations have been detected. Identification of additional causal genes and disease modifier genes is needed. Recently, mutations in mitochondrial DNA were reported in families with maternally inherited tubulointerstitial kidney disease, pointing to the potential role of mitochondria in tubulointerstitial changes 17 . In fact, mitochondrial dysregulation was reported in a mouse model of ADTKD-UMOD 62 . On the mechanistic side, major questions include the mechanisms causing kidney disease and progression in relation to the different genes involved; the identification of potential commonalities between the different subtypes of ADTKD; the need for novel and improved (humanized) cell and animal models to identify and test therapeutic strategies; the investigation of the potential benefit of nephroprotective therapies for patients with ADTKD; and the characterization of the role of involved genes in multifactorial CKD. The nature of profibrotic signals derived from the TAL cells remains largely elusive as does the sequence of events leading to abnormal matrix accumulation.
The relatively slow rate of progression of ADTKD is clinically beneficial but poses difficulty for researchers attempting to identify a treatment, as individuals may be reluctant to try a medication that has not previously been used in clinical practice. Thus, re-purposing of currently used medications is the best short-term option for success. Additionally, the slow rate of progression and the rarity of the condition complicate the possibility of performing a clinical trial with a primary endpoint based on renal function decline. These difficulties stress the importance of identifying biomarkers of disease activity in ADTKD. As the condition is not glomerular, there is no spillage of serum proteins into the urine. Thus far, promising biomarkers of ADTKD-UMOD include low levels of uromodulin in the urine, reflecting the formation of intracellular aggregates with mutant uromodulin, and increased urinary levels of the cysteine-rich with EGF-like domains 2 (CRELD2) protein, which is induced and secreted under ER stress 5, 53, 144 . ER stress markers could also be effective in other ADTKD forms in which this mechanism has been implicated such as in REN and SEC61A1 mutations.
A central question regarding ADTKD is whether the primary causal agent is a gain-of-toxic-function due to the mutated protein or the loss-of-function of the remaining wild-type allele. For ADTKD-UMOD and ADTKD-MUC1, knockout mice have been shown to have minimal or no kidney disease, and truncations of the wild-type protein have not been found in patients. ADTKD-UMOD results in accumulation of the mutant protein in the ER, where it stimulates the UPR and pathways of ER stress. ADTKD-MUC1 also involves the intracellular accumulation of mutant MUC1fs protein. The link between mutant uromodulin or MUC1fs and tubulointerstitial damage, the potential relationship between these two proteins, or the possibility of danger signals involved in crosstalk with other cell types remain to be deciphered. It should be noted that the mutant renin proteins also seem to be toxic to cells: in the few families with REN mutations described thus far, mutant proteins also accumulate diffusely in the cytoplasm and activate the UPR 10, 30 . Considering the gain-of-toxic-function effect of UMOD and MUC1 mutations, a possible strategy to counteract the disease course would be to decrease the production of mutant proteins, for instance, through the use of specific antisense oligonucleotides 145 . In the case of ADTKD-UMOD, where the accumulation of aggregates in the ER is clearly pathogenetic, the aim would be to decrease the amount of mutant uromodulin production whilst keeping a level of wild-type protein that would exert its physiological role in the urine. The tissue specificity of UMOD expression may offer a clear advantage over off-target effects, whereas targeted delivery would be crucial for MUC1 and REN mutations. An alternative approach could be the use of proteostasis modulators or of chemical chaperones. A first attempt with the well-known chaperone 4-PBA (see above) was not effective in a mouse model of ADTKD-UMOD, despite promising results in cell models 58 . A better understanding of the role of UPR activation (for example, whether it is adaptive or maladaptive) could enable testing of the effects of selective UPR modulators. A recent study showed that toxic accumulation of MUC1fs could be rescued by a small molecule targeting a cargo receptor (TMED9), re-routing the vesicles trapping MUC1fs into lysosomes, where they can be degraded 146 . Quenching the inflammatory process may also be an interesting option, as recently shown through selective inhibition of TNF signalling in an ADTKD-UMOD mouse model 64 . Gene-editing approaches to repair specific mutations, to rescue haploinsufficiency or to delete specific pathways, coupled to kidney delivery systems, also offer promising therapeutic strategies [147] [148] [149] . Taken together, appropriate disease awareness and availability of standardized diagnostics, increased knowledge about disease mechanisms, extra-renal manifestations and subclassifications, combined with a collaborative network of health-care providers and patients, will enable new targets and strategies to be identified for ADTKD. Moreover, we anticipate that research in ADTKD will yield valuable scientific information for other rare and common diseases, including mechanisms of kidney fibrosis and failure, and fundamental mechanisms arising from ER and proteostasis abnormalities.
